ArticleJapanese journal of ophthalmology2026
Evaluation of contamination in preservative-free multi-dose Brimonidine eye drops: a comparative study.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effectiveness of preservative-free multi-dose eye drop technology in preventing contamination. STUDY
designProspective study
methodsIn this study, the caps, first and second drops of preservative-free multidose brimonidine (PF-MDB) and multidose brimonidine with purite preservative (P-MDB) used by 54 glaucoma patients were analysed on both chocolate and sheep blood agar. The patients used the drops at 3-week intervals. The contents of the eye droppers were examined for contamination by piercing the bottom of the eye dropper in accordance with aseptic techniques.
resultsThe contamination levels detected using chocolate agar in the caps and the first drops of PF-MDBs were significantly higher than in P-MDBs (p=0.006 and p<0.001, respectively). The contamination levels detected using blood sheep agar in the caps and the first and second drops of PF-MDBs were significantly higher than in P-MDBs (p=0.001, ‹0.001, 0.006, respectively). No growth was found inside the eye dropper bottles of either PF-MDB or P-MDB drops. There was a significantly higher level of contamination in the first drops of PF-MDB compared to the second drops (p<0.001).
conclusionPF-MDB bottle technology effectively prevents microbial contamination in the bottle without preservatives. However, due to the lack of a preservative, there is increased bacterial and fungal growth associated with contamination on the cap, as well as in the first and second drops, compared to P-MDB.
Indexed as
Identifiers
41296207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.